A relatively new
approach in the treatment of specific wounds in
animal models and in patients with type A
botulinum toxin is the focus of this paper. The
indications or conditions include traumatic
wounds (experimental and clinical), surgical
(incision) wounds, and wounds such as fissures
and ulcers that are signs/symptoms of disease or
other processes. An objective was to conduct
systematic literature searches and take note of
the reactions involved in the healing process
and identify corresponding pharmacokinetic data.
From several case reports, we developed a
qualitative model of how botulinum toxin
disrupts the vicious cycle of muscle spasm,
pain, inflammation, decreased blood flow, and
ischemia. We transformed this model into a
minimal kinetic scheme for healing chronic
wounds. The model helped us to estimate the rate
of decline of this toxin's therapeutic
effect by calculating the rate of recurrence of
clinical symptoms after a wound-healing
treatment with this neurotoxin.